TABLE 4.

Cox proportional hazard analysis for PFS and OS in mCRC patients treated with second‐line chemotherapy

PFS	Univariate analysis				Multivariate analysis
	HR	Lower 95% CI	Upper 95% CI	p value		HR	Lower 95% CI	Upper 95% CI	p value
Sex (Female* or Male)	0.85	0.63	1.15	0.29
Age (<65* or ≥65)	0.96	0.71	1.29	0.76
Primary tumor location (Left* or Right)	1.35	0.99	1.86	0.06
Liver metastasis (Negative* or Positive)	1.50	1.11	2.02	0.008		1.47	1.10	1.97	0.01
Lung metastasis (Negative* or Positive)	0.92	0.68	1.24	0.58
Peritoneal metastasis (Negative* or Positive)	1.21	0.89	1.65	0.22
Lymph node metastasis (Negative* or Positive)	1.15	0.84	1.57	0.37
Tissue RAS mutation (Negative* or Positive)	0.91	0.67	1.23	0.54
Prior bevacizumab exposure in first‐line chemotherapy (Negative* or Positive)	1.51	1.11	2.04	0.008		1.52	1.13	2.05	0.006
Grade 3 or 4 adverse events within the first four cycles of treatment (Negative* or Positive)	0.58	0.44	0.78	0.0003		0.57	0.43	0.77	0.0002
Treatment regimen (Bevacizumab or other*)	1.10	0.83	1.46	0.51

OS	Univariate analysis				Multivariate analysis
	HR	Lower 95% CI	Upper 95% CI	p value	HR	Lower 95% CI	Upper 95% CI	p value
Sex (Female* or Male)	1.04	0.70	1.55	0.85
Age (<65* or ≥65)	0.93	0.62	1.39	0.73
Primary tumor location (Left* or Right)	1.33	0.87	2.04	0.18
Liver metastasis (Negative* or Positive)	2.26	1.45	3.44	0.0001	2.34	1.55	3.54	0.00006
Lung metastasis (Negative* or Positive)	0.87	0.58		0.51
Peritoneal metastasis (Negative* or Positive)	0.92	0.60	1.42	0.72
Tissue RAS mutation (Negative* or Positive)	1.19	0.78	1.82	0.41
Prior bevacizumab exposure in first‐line chemotherapy (Negative* or Positive)	1.45	0.96	2.18	0.07
Grade 3 or 4 adverse events within the first four cycles of treatment (Negative* or Positive)	0.44	0.29	0.67	0.0001	0.44	0.29	0.66	0.00009
Treatment regimen (Bevacizumab or other*)	0.93	0.63	1.36	0.69